Kimball Electronics, Inc. (KE) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a mix of positive and negative factors. Strong adjusted income and net income, debt reduction, and cash flow are positives. However, the guidance for fiscal 2026 indicates revenue decline and modest growth in key segments. The Q&A reveals positive sentiment towards medical growth and strategic acquisitions, but concerns in the automotive sector and potential SG&A increase. Overall, the outlook is mixed with stable margins and strategic growth plans, leading to a neutral sentiment.
Key Financial Performance
Net Sales $366 million, a 2% decline compared to Q1 fiscal '25. The decline was due to strong results in Medical being offset by declines in Automotive and Industrial.
Medical Sales $102 million, up 13% compared to the same period last year. Growth was driven by robust sales growth in Asia and Europe, while North America was up mid-single digits.
Automotive Sales $164 million, down 10% compared to the first quarter of last year. The decline was due to lower sales in North America (resulting from the electronic braking program transfer) and a decline in Asia, partially offset by strong sales growth in Europe.
Industrial Sales $100 million, a 1% decrease compared to Q1 last year. The decline was due to softening demand for HVAC driven by the slowing housing market in North America and a significant decline in Europe, partially offset by strong sales growth in Asia.
Gross Margin Rate 7.9%, a 160 basis point increase compared to 6.3% in the same period of fiscal 2025. The improvement was driven by favorable product mix, the closure of the Tampa facility, and global restructuring efforts.
Adjusted Selling and Administrative Expenses $11.3 million, nearly flat year-over-year. As a percentage of sales, the rate was 3.1% this year compared to 2.9% last year. A $2 million recovery was recorded due to a customer termination of a program.
Adjusted Income $17.5 million or 4.8% of net sales, compared to $12.6 million or 3.4% of net sales last year. The increase was due to efforts to rightsize expenses, reduce debt, and take advantage of tax opportunities.
Adjusted Net Income $12.3 million or $0.49 per diluted share, up 2x from last year's adjusted results of $5.5 million or $0.22 per diluted share. The increase was attributed to expense management, debt reduction, and tax opportunities.
Cash and Cash Equivalents $75.7 million as of September 30, 2025. Cash generated by operating activities in the quarter was $8.1 million, marking the seventh consecutive quarter of positive cash flow.
Inventory $272.7 million, roughly flat versus Q4 but down $62.6 million or 19% from a year ago.
Borrowings $138 million, a $9.5 million reduction from the fourth quarter and down $108 million or 44% from a year ago.
Capital Expenditures $10.6 million in the first quarter, primarily for leasehold improvements in the new facility in Indianapolis.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Medical vertical expansion: Sales in the medical vertical reached $102 million, up 13% year-over-year, driven by growth in Asia, Europe, and North America. The company is expanding production capabilities beyond electronics into higher-level assemblies and finished medical devices. A new medical facility in Indianapolis will add capacity for manufacturing medical products, including single-use surgical instruments and drug delivery devices.
Geographic diversification in medical: Medical sales were nearly evenly split between North America, Asia, and Europe, with robust growth in Asia and Europe and mid-single-digit growth in North America.
Operational efficiencies: Gross margin improved to 7.9%, up 160 basis points year-over-year, driven by favorable product mix, facility closures, and restructuring efforts. Cash from operations was positive for the seventh consecutive quarter, and debt levels were the lowest in over three years.
Inventory and cash flow management: Inventory decreased by 19% year-over-year, and cash conversion days improved by 25 days compared to the previous year.
Focus on medical market: The company is prioritizing growth in the medical market, leveraging its expertise in a regulated industry and targeting opportunities in aging populations and advanced medical devices. It is also pursuing inorganic growth through potential acquisitions to expand into new markets and geographies.
Tariff management: The company is addressing increased tariffs by passing costs to customers and monitoring geopolitical developments. Additional restructuring costs may be incurred to maintain profitability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Automotive Sales Decline: Sales in the automotive sector decreased by 10% compared to the previous year, driven by lower sales in North America due to the electronic braking program transfer and a decline in Asia. This poses a risk to revenue stability in this vertical.
Industrial Sales Softening: The industrial sector experienced a 1% decline in sales, with softening demand for HVAC products in North America due to the slowing housing market. This could impact revenue from this segment.
Tariff Impacts: The evolving global tariff landscape, including new U.S. tariffs implemented in February 2025, may impact end consumer demand and operating results if costs cannot be fully passed on to customers.
Restructuring Costs: The company expects to incur additional restructuring costs over the fiscal year to address challenges related to tariffs and other operational pressures, which could impact profitability.
Medical Expansion Risks: While the medical sector is growing, the company is investing heavily in new facilities and capabilities, including inorganic growth strategies. These investments carry risks related to execution, cost overruns, and integration challenges.
Foreign Exchange Volatility: Foreign exchange had a 1% favorable impact on sales this quarter, but ongoing currency fluctuations could pose risks to financial performance.
Softening U.S. Housing Market: The slowing housing market in North America is negatively affecting demand for HVAC products, which could continue to pressure the industrial segment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Net sales for fiscal 2026 are expected to be in the range of $1.35 billion to $1.45 billion.
Margin Projections: Adjusted operating income is projected to be 4% to 4.25% of net sales for fiscal 2026.
Capital Expenditures: Estimated capital expenditures for fiscal 2026 are between $50 million and $60 million.
Medical Segment Growth: The company expects continued growth in the medical segment, driven by production capabilities beyond electronics and printed circuit boards, expanding into higher-level assemblies and finished medical devices. The new medical facility in Indianapolis will add capacity for manufacturing medical products, single-use surgical instruments, and drug delivery devices such as autoinjectors.
Automotive Segment Outlook: Long-term growth is expected in the automotive segment, particularly as new systems and technologies such as steer-by-wire and brake-by-wire continue to increase the electronic content in vehicles.
Industrial Segment Trends: Softening demand for HVAC driven by the slowing housing market is expected to continue impacting the industrial segment in North America.
Tariff Impact: The company anticipates recovering increased tariff costs by passing them on to customers but acknowledges potential adverse impacts on operating results and cash flows if full recovery is not achieved.
Strategic Growth Plans: The company plans to pursue growth through both organic and inorganic channels, including a tuck-in acquisition strategy to add new end markets, manufacturing capabilities, and customer relationships.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: We invested $1.5 million in Q1 to repurchase 49,000 shares. Since October 2015, under our Board-authorized share repurchase program, a total of $105.2 million has been returned to our shareowners by purchasing 6.7 million shares of common stock. We have $14.8 million remaining on the repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:As Kimball resumes top-line growth, should we expect an increase in working capital?
A:Yes, as Kimball prepares for growth in FY '27, there will be a need to buy inventory, which will increase working capital. However, this is seen as a positive sign of growth.
Q:Will cash conversion days remain stable?
A:Ideally, the company would like cash conversion days to have a '7' in front of it, but realistically, stabilizing in the very low 80s is acceptable, especially as the business starts to grow again.
Q:Is it correct to model EBITDA margin declining further next year?
A:No, management does not expect a deterioration in EBITDA margin. They anticipate better absorption in facilities and additional restructuring in FY '26, leading to improved EBITDA in FY '27.
Q:What is the focus of potential acquisitions in the Medical segment?
A:The focus is on the medical CMO space, including new technologies, customers, and geographies that extend capabilities and allow a bigger role with customers.
Q:What is the outlook for industrial growth?
A:Industrial growth is expected to be softer than previously anticipated, with Q1 results serving as a proxy for full-year FY '26. Medical growth will be stronger, and automotive will perform as expected.
Q:How did the largest medical customer in respiratory care perform?
A:The performance was very good, with a strong partnership and continued growth expected.
Q:What is the pipeline of medical projects turning into revenue over the next 6 months?
A:The pipeline is strong, with high volume and growth spread across multiple programs, customers, and geographies, including Europe, Asia, and North America.
Q:What is the outlook for the core automotive business?
A:The automotive market faces challenges over the next couple of years, but the company is well-positioned in areas with added electronic content and strong customer relationships.
Q:How is the company balancing inorganic growth and organic operations improvement?
A:The company is focused on disciplined capital allocation, leveraging its existing manufacturing footprint, and considering inorganic opportunities that align with its CMO strategy without compromising the balance sheet.
Q:Is accelerated depreciation impactful for the company?
A:Yes, it is impactful, particularly in terms of interest expense deductions on domestic income and potential R&D credits.
Q:What contributed to gross margin expansion despite lower revenue?
A:Favorable product mix, better absorption and utilization, benefits from restructuring, and closing the Tampa facility contributed to gross margin expansion.
Q:Will SG&A increase as a percentage of sales for the rest of the year?
A:Yes, SG&A will increase to support growth, focusing on technology and business development.
Q:What is the outlook for debt reduction?
A:Debt is expected to climb slightly next quarter due to inventory needs for FY '27 growth, but this is seen as a positive sign of preparation for growth.
Q:How has the M&A market changed recently?
A:The M&A market has become more rational, with strategic buyers like the company feeling better about acquiring opportunities at reasonable price points.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to whether the automotive segment has bottomed, citing challenges in the overall automotive market and external pressures such as tariffs and economic impacts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Asia Europe
Asia sale
Cash
Industrial
Kimball Electronics
Medical
Sales
braking program
cash equivalent
cash flow
course
day improvement
demand tariff
device
digit
end market
environment
expenditure
facility Indianapolis
housing market
income sale
industry
percentage
rate tax
sale North
share
split
strength
tax opportunity
term
vehicle
wire
KE Transcript
Kimball Electronics, Inc. (KE) Q3 2026 Earnings Call Transcript
Positive5-6
The earnings call summary highlights a strong financial performance with a 10% revenue increase and improved gross margins, leading to a 15% rise in net income. The positive financial metrics, along with increased operating cash flow, suggest a healthy financial position. Despite the absence of detailed strategic initiatives, the financial results and raised guidance for fiscal 2026 are likely to result in a positive stock price movement. However, the lack of additional insights from the Q&A section and strategic updates tempers the rating to 'Positive' instead of 'Strong positive.'
Kimball Electronics, Inc. (KE) Q2 2026 Earnings Call Transcript
Unknown2-5
The earnings call presents a mixed picture: strong growth in the medical segment and improved gross margins are positive, but overall net sales declined, and automotive sales are down. The shareholder return plan is positive, but the Q&A reveals uncertainties about the new facility's impact on margins and revenue. The market reaction is likely to be neutral, with offsetting positive and negative factors balancing each other out.
Kimball Electronics, Inc. (KE) Q1 2026 Earnings Call Transcript
Unknown11-6
The earnings call highlights a mix of positive and negative factors. Strong adjusted income and net income, debt reduction, and cash flow are positives. However, the guidance for fiscal 2026 indicates revenue decline and modest growth in key segments. The Q&A reveals positive sentiment towards medical growth and strategic acquisitions, but concerns in the automotive sector and potential SG&A increase. Overall, the outlook is mixed with stable margins and strategic growth plans, leading to a neutral sentiment.
Kimball Electronics, Inc. (KE) Q4 2025 Earnings Conference Call Transcript
Positive8-14
The earnings call highlights a robust strategy with new facility expansion, strong focus on the medical segment, and margin improvement efforts. The Q&A reveals positive sentiment towards automation and growth initiatives, despite some vague responses on industrial plans. The reiteration of fiscal guidance, coupled with strategic investments in sales and business development, supports a positive outlook. The absence of negative financial surprises and the focus on high-growth segments suggest a positive stock price movement in the short term.
KE Slides
KE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
